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Introduction
　The tumor stroma includes various types of 
cells, such as leukocytes, lymphocytes, mac-
rophages, ﬁbroblasts, and endothelial cells (ECs). 
Tumor stromal cells are different from their nor-
mal counterparts.  For example, cancer-associated 
ﬁbroblasts (CAF) promote cancer progression1, 
and tumor-associated macrophages (TAM) produce 
epithelial growth factor (EGF), which stimulates 
tumor cell migration in breast cancer2 (Fig. 1).
　Angiogenesis, the process of new blood-vessel 
growth, is necessary for tumor progression and 
metastasis.  Tumor blood vessels provide nutrition 
and oxygen, and get rid of waste from tumor tis-
sue, resulting in tumor progression.  In addition, 
tumor vessels act as gatekeepers for tumor cells to 
metastasize to distant organs3,4.
　Thus, the attempt to target tumor endothelial 
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Abstract : Tumor blood vessels play an important role in tumor progression and metastasis.  Thus, 
targeting tumor blood vessels is an important strategy for cancer therapy, especially for head and 
neck cancer patients.  Tumor blood vessels generally sprout from pre-existing vessels and have 
been thought to be genetically normal.  However, tumor blood vessels have been shown to differ 
from their normal counterparts, for example, by changes in morphology.  The authors isolated tu-
mor endothelial cells (TECs) from mouse tumor xenografts and have shown that the TECs are ab-
normal.  TECs up-regulate many genes and proliferate more rapidly and migrate more than nor-
mal endothelial cells (NECs).  Furthermore, TECs were found to be cytogenetically abnormal.  We 
conclude that TECs can acquire cytogenetic abnormalities while in a tumor microenvironment.
　To develop ideal antiangiogenic therapies, understanding the crosstalk between blood vessels 
and the tumor microenvironment is important.
　Here, we provide an overview of the current studies on TEC abnormalities and a discussion 
about possible mechanisms for how tumor the microenvironment makes TECs abnormal.
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cells (TECs) with angiogenic inhibitors (antiangio-
genic therapy) has been an important strategy for 
cancer therapy, and many antiangiogenic drugs 
have been discovered and tested to date5.
　Traditionally, TECs have been believed to be 
genetically stable and may not acquire drug resis-
tance unlike tumor cells, until recently.  However, 
recent studies suggest that TECs differ from 
NECs and are also heterogeneous among organs 
or tumor types.
　We previously found that TECs, which are also 
components of the tumor stroma, are different 
from normal endothelial cells (NECs)6-8.  For 
example, they up-regulate speciﬁc markers such 
as TEC markers (tumor endothelial markers 
(TEMs) and vascular endothelial growth factor 
receptor (VEGFR)-29,10.  Interestingly, human 
renal TECs are more proliferative and resistant to 
serum starvation with overexpressed VEGF-D and 
activated Akt phosphorylation, suggesting that 
TECs are stimulated in an autocrine manner11. 
Furthermore, we found that TECs are cytogeneti-
cally abnormal6,12, we conclude that TECs can 
acquire these abnormalities while in the tumor 
microenvironment.
　To develop ideal tumor antiangiogenic thera-
pies, understanding the biology of TECs and the 
interaction between TECs and the tumor microen-
vironment are very important.
1. Phenotype of tumor blood vessels
　It is well documented that tumor blood vessels 
differ morphologically from normal blood vessels 
(Fig. 2).  Tumor blood vessels are often tortuous 
in appearance with uneven vessel diameters due 
in part to compression of the immature vessel wall 
by tumor cells.  Tumor vessels exhibit chaotic 
blood ﬂow and vessel leakiness due to loose 
endothelial cell interconnections13.  Tumor vessels 
are also unorganized whereas the normal vascu-
lature shows a hierarchal branching pattern of 
arteries, veins and capillaries14.  TECs do not form 
Fig. 1　Cells interacting with each other in tumor microenvironment
There are various types of cells in primary tumor tissue ; tumor-associated macrophages (TAM), can-
cer-associated ﬁbroblasts (CAF), immune cells, pericyte and tumor endothelial cells (TECs), and tumor 
cells. They secrete growth factors or cytokines to communicate to each other. TECs are exposed to 
these factors and educated from tumor cells and other stromal cells.
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regular monolayers and thus do not have a normal 
barrier function15.  Pericytes are present on TECs, 
but have abnormal loose associations with these 
cells and extend cytoplasmic processes deep into 
the tumor tissue16.  These abnormalities result in 
leakiness of tumor blood vessels.  The high inter-
stitial ﬂuid pressure in tumor causes blood vessel 
collapse and thus impedes blood ﬂow.  This is one 
reason why tumor tissue is usually under an 
hypoxic condition, even though it is highly vascu-
larized.  This sometimes causes resistance to radi-
ation therapy17.
2. Abnormality of TECs
　The presence (existence) of morphological 
abnormalities in tumor blood vessels compared 
to normal blood vessels raises questions as to 
whether there are phenotypical differences at the 
molecular and functional levels between TECs 
and NECs.  To examine this question, TECs iso-
lated from tumor tissue are required.  However, 
there have not been many reports about the isola-
tion of TECs until recently.  In fact, most studies 
on tumor angiogenesis have long been done using 
NECs such as human umbilical vein endothelial 
cells (HUVEC) or human dermal microvascular 
endothelial cells (HMVEC).  Isolating TECs has 
been difﬁcult because of the technical difﬁculties 
involved.  In addition, there have been concerns 
about (the effectiveness of) trials to isolate TECs 
themselves, because they were sometimes consid-
ered to lose their speciﬁc phenotype soon after 
being isolated from tumor tissue.  In the ﬁrst 
report concerning tumor endothelial specific 
markers, St. Croix et al. succeeded in isolating 
endothelial cells from colon carcinoma and normal 
Fig. 2　Differences between blood vessels in tumor and normal tissues
Tumor vessels have (exhibit) excessive branching. Pericytes have abnormally loose associations with en-
dothelial cells and extend cytoplasmic processes deep into the tumor tissue. Tumor vasculature shows a 
lack of arteriole-capillary-venule hierarchy. Tumor vessels exhibit chaotic blood ﬂow.
In addition, tumor endothelial cells (TECs) differ from normal endothelial cells.
1) TECs grow faster with lower serum requirement. 2) TECs respond to growth factors well. 3) TECs ex-
press speciﬁc genes, such as TEMs and EGFR. 4) TECs have cytogenetical abnormalities. 5) TECs are 
resistant to chemotherapeutic drugs.
(Modiﬁed from ref. 9.)
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colonic mucosa and compared the gene expression 
proﬁles between TECs and NECs of a relatively 
low number of cells.  They identiﬁed the speciﬁc 
genes for TECs and designated them as tumor 
endothelial markers (TEMs)18.  Some of them are 
transmembrane proteins and are also conserved 
in mice19,20.  Very recently, they showed that 
these TEMs, except for TEM8, are also overex-
pressed during physiological angiogenesis, as well 
as in TECs.  Instead, they identiﬁed 13 novel cell 
surface proteins as TEMs21.  There have also been 
several reports about the gene proﬁle of TECs 
using global analysis21-24.
　However, TECs were not cultured in these stud-
ies and the biological phenotype in TECs remains 
to be clariﬁed.  We have isolated TECs in an 
attempt to better understand the effects of the 
tumor microenvironment on endothelial cell prop-
erties7.  Human tumor xenograft models in nude 
mice were established as sources of mouse TECs. 
Murine TECs (Oral carcinoma EC, Renal carci-
noma EC, Melanoma EC, and Liposarcoma EC) 
and NECs (skin EC) were isolated using magnetic 
bead cell sorting6,10.  The mouse TECs expressed 
typical endothelial cell markers such as CD31, 
VEGF receptors and upregulated several tumor 
endothelial markers which have already been 
reported, such as TEM86 or  Aminopeptidase N: 
CD13 even after long term culturing10.  From 
these data, TECs were found to retain their speci-
ﬁcity for TECs (at least in some cases) even in cul-
ture.  TECs grew and migrated more quickly (Fig. 
3)10.  In addition, TECs were more responsive to 
angiogenic growth factors such as basic ﬁbloblast 
growth factor (bFGF)7 and VEGF compared to 
NECs10.  Furthermore, we have found that express 
high levels of EGF receptors (EGFR), which are 
not usually expressed in NECs, such as HUVEC25. 
EGF can induce phosphorylation of TEC EGFR 
and stimulate TEC proliferation.  EGFR tyrosine 
kinase inhibitors inhibit EGF-induced EGFR acti-
vation and proliferation of TECs25.
　Taking the in vivo and in vitro studies together, 
there is mounting evidence that there are distinct 
differences between tumor and normal blood ves-
sels and their endothelial cells in terms of biology, 
morphology and gene proﬁles (Fig. 2).
3. TECs have cytogenetical abnormalities
　Strikingly, the TECs examined were found to be 
cytogenetically abnormal6.  The TECs were karyo-
typically aneuploid, whereas NECs grown under 
the same conditions were diploid.  In addition, 
multiple colored ﬂuorescent in situ hybridization 
Fig. 3　TECs show higher proliferation and motility compared to NECs
(A) Cell proliferation assay demonstrates that TECs grow faster than NECs (＊p ＜ 0.01). (B) Wound-healing assay 
demonstrates that the motility of TECs is higher than that of NECs. ECs were incubated for 12 hours after admin-
istration of the scratch. Scale bar ; 50 μm.  (Modiﬁed, from ref. 10.)
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(M-FISH) analysis showed that the TECs had 
structural aberrations such as non-reciprocal 
translocations, showing hallmarks of chromosomal 
instability6.  To avoid possible artifacts due to 
culture conditions, freshly isolated, uncultured 
endothelial cells were analyzed by FISH.  CD31 
staining was used to conﬁrm endothelial cell iden-
tity.  About 16％ of liposarcoma endothelial cells 
and 34％ of melanoma endothelial cells were 
found to be aneuploid by FISH using a mouse 
chromosome 17 probe6.  After this report, we 
recently investigated the aneuploidy of other types 
of TECs.  About 35％ of oral carcinoma endothe-
lial cells (Fig. 4A) and 54％ of renal carcinoma 
endothelial cells (Fig. 4B) were also found to be 
aneuploid even when uncultured, whereas skin 
EC showed only 4％ aneuploidy which is in the 
normal range of FISH analysis using this type of 
probe (Fig. 4C).
　These results suggest that TECs, unlike NECs, 
have chromosomal instability.
　Since TECs continue to proliferate in culture, 
it appears that these cells, like tumor cells, lack 
the normal cell cycle checkpoints that inhibit 
mitosis in response to chromosomal abnormalities. 
Recently we found that TECs also showed aneu-
ploidy in human renal cell carcinomas as well as 
mouse TECs (Fig. 5)12.
　There are some other reports concerning chro-
mosomal abnormalities in TECs in hematopoietc 
Fig. 4　TECs with cytogenetical abnormality
Mouse oral carcinoma endothelial cells (A) and 
renal carcinoma endothelial cells (B) were iso-
lated and cytospun onto glass slides, followed 
by immunostaining with an anti-CD31antibody 
and FISH with a chromosome 17 probe. Repre-
sentative aneuploid endothelial cells are shown. 
NECs (skin endothelial cells) are diploid (C).  
Green ; CD31, Red ; chromosome 17, Blue ; Dapi,  
Bar ; 10 μm.
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tumors such as leukemia26 and lymphoma27.  In 
chronic myeloid leukemia, for example, circulating 
endothelial cells had leukemia-speciﬁc transloca-
tions26.  In B-cell lymphomas, 37％ of endothelial 
cells were shown to harbor lymphoma-speciﬁc 
chromosomal translocations, suggesting that lym-
phoma and lymphoma endothelial cells may both 
be derived from hemangioblastic cells27.  In addi-
tion, circulating endothelial cells in multiple 
myeloma had the same translocation as myeloma 
cells, indicating the possibility that both cells were 
originally from the same multipotent hemangio-
blast28.
　Furthermore, a recent study reported that neuro-
blastoma endothelial cells had a varying proportion 
of microvascular endothelial cells that exhibited 
MYCN ampliﬁcation, which are typically ampliﬁed 
in neuroblastoma, suggesting that these TECs 
are dedifferentiated from their tumor origin29.
4. Signiﬁcance of TEC aneuploidy
　An abnormal chromosome number, aneuploidy, 
is a common characteristic of tumor cells.  In 
addition, it has been proposed that aneuploidy 
Fig. 5　FISH analysis in freshly isolated and cytospun human TECs and NECs
FISH analysis of freshly isolated and cytospun hTECs and hNECs. hTECs and hNECs were stained 
for CD31 or the RCC marker CA IX. FISH was performed using chromosome 7 (red) and chromosome 
8 (yellow) DNA probes. Nuclei were counterstained with DAPI (blue). hNECs and hTECs were positive 
for CD31. No CA IX expression was observed in hNECs and hTECs. In FISH analysis, three or more 
chromosome 7 (red) and chromosome 8 (yellow) signals were detected in hTECs, indicating aneuploidy 
(upper panels). On the other hand, hNECs showed two signals, indicating diploidy (middle panels). 
Tumor cells (CA IX＋CD31－cells with aneuploidy) were detected in the negative fraction of primary 
EC isolates (bottom panels).  (Modiﬁed from ref. 12.)
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causes tumorigenesis for nearly 100 years.  How-
ever, this remains unproven since there have been 
controversial reports that aneuploidy is merely a 
benign side effect of transformation or a contribu-
tor to tumor progression, but not to tumor initia-
tion30.  Recently, Weaver et al. generated aneu-
ploid cells in animals by reducing Centromere-
associated Protein-E (CENP-E).  In their study, 
aneuploidy was shown to promote spontaneous 
tumorigenesis in aged animals, but at a modest 
frequency.  However, an increased rate of aneu-
ploidy was shown to inhibit tumorigenesis31.
　Regarding with TECs that we isolated, mRNA 
levels of CENP-E were found to be down-regulated 
in human TECs, compared to NECs12.
　TECs have long been considered to be geneti-
cally normal, unlike tumor cells.  However, aneu-
ploid TECs may be a different matter.  TECs may 
develop drug resistance like tumor cells, contrary 
to past beliefs.  It has been shown previously that 
TECs in culture are more resistant to vincristine 
than NECs11.  Our studies also showed that TECs 
were more resistant to 5-FU than NECs (unpub-
lished data).
　Some antiangiogenic drugs have been shown to 
lose their effectiveness over time, possibly due to 
acquired resistance.  Contrary to the presumption 
that antianigogenic drugs are not as toxic as 
cytotoxic drugs, they have been reported to cause 
severe side effects such as lethal hemoptysis32,33 
and perforation of the intestines34,35.
　For example, as a mechanism of resistance to 
antiangiogenic therapy, it was suggested that sur-
vival factors such as cytokines or growth factors 
which are rich in the tumor microenvironment, 
may cause epigenetic changes not only in tumor 
cells, but also in TECs36.  For example, bFGF 
was reported to inhibit apoptosis signal kinase 
1 (ASK1) activity, inducing chemoresistance in 
HUVEC37.
　Taken together, the possibility that aneuploid 
TECs are chemotherapy-resistant (or sensitive to 
some drugs) warrants further investigation.
5.  Crosstalk between TECs and tumor micro-
environment
　The mechanisms that result in TEC aneupolidy 
are not yet understood.  Understanding how 
endothelial cells are educated from tumor cells or 
other tumor stromal cells is very important.  Pos-
sible mechanisms include the following :
　i) Tumor cell transdifferentiation : In the case of 
hematopoietic tumors such as human B-cell lym-
phomas and multiple myeloma, a common progen-
itor targeted by transformation can differentiate 
in tumor cells or endothelial cells26,28.  In addition, 
tumor cells may dedifferentiate to endothelial 
cells.  This mechanism may be applied to neuro-
blastoma endothelial cells that harbor the same 
chromosome ampliﬁcation as tumor cells29.  How-
ever, these possibilities are not likely in our cases 
as the tumors are of non-hematopoietic origin.  In 
addition, in our cross-species tumor model, the 
mouse origin of endothelial cells was shown rela-
tively easily, since the probe for FISH or multi-
color FISH is mouse-speciﬁc.
　ii) Tumor microenvironment : Factors such as 
growth factors or cytokines in the tumor micro-
environment may cause genetic instability.  For 
example, VEGF, bFGF and EGFR ligands 
expressed in tumor and stromal cells are anti-
apoptotic survival factors that activate the sur-
vival signal transduction pathway and up-regulate 
oncogene expression, causing genetic instabil-
ity37,38.  Bcl-2 is overexpressed in TECs and 
induces VEGF, stimulating VEGFR-1 on tumor 
cell surface.  Bcl-2 is also up-regulated through 
VEGR-1 signaling, and then proangiogenic 
chemokines, such as CXCL1 and CXCL8, are 
induced in tumor cells39.  This study suggests 
that there is a regulator between tumor cells and 
TECs.  In addition, the hypoxic condition in 
tumor tissue is known to cause genetic changes, 
for example up-regulation of survival factors, in 
tumor cells40.  Thus, the tumor microenvironment 
can induce genetic instability in not only tumor 
cells, but also endothelial cells.
　iii) Cell fusion : malignant tumor cells can fuse 
with NECs or circulating endothelial progenitor 
cells.  In a human breast carcinoma xenograft 
model in mice, the ﬁbroblasts were aneuploid har-
boring both mouse and human chromosomes, sug-
gesting these cells were fused with tumor cells41. 
In the case of our cultured TECs, this was not 
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applicable, since the mouse aneuploid TECs were 
not hybridized to a human genome probe for 
FISH12.
　iv) Uptake of oncogene or gene transfer : 
Endothelial cells can uptake human tumor onco-
genes by phagocytosis of apoptotic bodies42.  Fur-
thermore, it has been suggested that genes can 
be transferred by tumor-derived microvesicles 
(MV)43.  Furthermore, it was reported that EPC 
released MV can activate endothelial cell angio-
genic properties44.
　v) Stem cells : Adult stem cells have been 
reported to fuse with mature cells such as hepato-
cytes, and show aneuploidy45.  Tumor stem cells 
may receive signals in the tumor microenviron-
ment triggering transdifferentiton.  Furthermore, 
it has been suggested that endothelial progenitor 
cells (EPC), a subset of stem cells derived from 
bone marrow, can be incorporated into tumor 
blood vessels46-48.  Especially, EPC plays an 
important role in early neovascularization49.  It is 
possible that some of the aneuploid TECs are 
EPC-derived.  Our TECs up-regulate the stem 
cell marker (Sca-1)10 gene, suggesting that they 
are differentiated from progenitor cells, at least 
in part.  The mechanisms such as cell fusion or 
gene transfer described above might also be appli-
cable in EPC.
　It is also possible that these EPC-derived 
endothelial cells have been selected in culture 
and show an increased rate of aneuploidy.
　In conclusion, TECs are different from NECs in 
gene proﬁle and behavior, in addition to the mor-
phological changes described previously.  Further-
more, the endothelial cells even in non-hematopoi-
etic tumors also have cytogenetic abnormalities, 
contrary to the assumption that TECs are geneti-
cally stable and thus not drug-resistant.  It is 
speculated that drug-resistance could possibly 
develop and compromise the effectiveness of 
antiangiogenic therapies.  Whatever mechanism 
underlies TEC abnormality, it is important to 
understand even stromal cells can be abnormal in 
the tumor microenvironment.  Recent studies sug-
gest that both tumor cells and stromal cells in the 
tumor microenvironment are targets for cancer 
therapy.  Studies on TEC abnormalities will help 
to develop ideal antiangiogenic therapies and also 
to understand how tumor tissues are orchestrated 
by various cell types in the tumor microenvirone-
ment.
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